Press Releases

Press Releases

    Date Title View
    03/16/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    PDF Version
    03/14/23
    Summary ToggleNew Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    03/12/23
    Summary ToggleReal-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
    PDF Version
    03/01/23
    Summary ToggleHorizon Therapeutics plc - Rule 2.12 Announcement
    PDF Version
    03/01/23
    Summary ToggleHorizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
    PDF Version
    02/28/23
    Summary ToggleHorizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
    PDF Version
    02/24/23
    Summary ToggleHorizon Therapeutics plc Announces Voting Results from Special Shareholder Meetings
    PDF Version
    02/23/23
    Summary ToggleNew Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines
    PDF Version
    01/30/23
    Summary ToggleHorizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
    PDF Version
    01/27/23
    Summary ToggleRule 15 (c) Announcement – Horizon Therapeutics plc
    PDF Version
    Displaying 1 - 10 of 727 results